Modern GLP-1 medicines are produced using recombinant DNA technology, where genetically modified yeast or bacterial cells produce the peptide in controlled fermentation tanks
Experts also point out that there have been no placebo-controlled clinical studies in this population to date and more quality research is needed
I rarely do that, although I did like, you know, if you go to like all, you can eat Korean barbecue and you're eating, I don't know, 400 grams of ribeye, you're probably overloading the circuits a little bit
Winning the new shape of demand will require targeting and appealing to each segment differently, rather than treating GLP-1 users as a single, homogeneous consumer group, says Lauren Taylor, a BCG managing director and senior partner who leads CCI globally
doi: 10.2353/ajpath.2009.080864 93 PytelDMajsterekIDiehlJA